Gilead Sciences (NASDAQ:GILD) Price Target Raised to $160.00

Gilead Sciences (NASDAQ:GILD) had its price target boosted by TD Cowen from $145.00 to $160.00 in a research report released on Wednesday morning,MarketScreener reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on GILD. Citigroup boosted their price target on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. UBS Group boosted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday. Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Scotiabank upped their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $152.42.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $154.98 on Wednesday. The firm’s fifty day simple moving average is $130.27 and its 200 day simple moving average is $122.27. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $157.29. The firm has a market capitalization of $192.28 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 1.22 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the company posted $1.90 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Insiders Place Their Bets

In other news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider directly owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 319,391 shares of company stock worth $44,141,101. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the company. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $26,000. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the second quarter worth about $27,000. Finally, Ares Financial Consulting LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. 83.67% of the stock is currently owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.